NCT01552798终止3 期
A Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single Dose of Fast Release Aspirin 1000 mg and Acetaminophen 1000 mg in Tension Type Headache Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Bayer
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)
研究概览
简要总结
The purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, ambulatory, male and female volunteers ages 18-65 years old
- •History of an onset of tension type headaches before age 50
- •Experiencing over the last year ≥ 4 tension type headaches of at least moderate intensity per month and with the majority of headaches lasting greater than three hours, that meet commonly recognized criteria for diagnosis per the International Headache Society
- •History of response to treatment with over-the-counter (OTC) analgesics
- •Understand the pain rating scales (as judged by the trial coordinator)
- •Present with at least moderate headache pain on a 0-10 point numerical rating scale (a score of at least 4 on an 11 point scale ranging from 0 to 10) at the Treatment Visit
- •Onset of pain within three hours of the Treatment Visit
- •Confirmation by a physician of acute tension type headache symptoms as described by the International Headache Society diagnostic criteria
排除标准
- •History of hypersensitivity to aspirin, salicylates, other NSAIDs, acetaminophen, and similar pharmacological agents or components of the investigational products, including the placebo
- •Use of any immediate release analgesic/anti-pyretic within four hours or use of any sustained release or long acting analgesic/anti-pyretic within 12 hours proceeding administration of Investigational Product
- •Presence of symptoms that are consistent with menstrual headache or migraine headache as described by the International Headache Society diagnostic criteria
- •History of migraine headaches more than once per month
- •Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the trial in the judgment of the Investigator
- •Current or past history of bleeding disorder(s)
- •History of gastrointestinal bleeding or perforation, related to previous Nonsteroidal Anti-inflammatory Drugs (NSAID) therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding)
- •Recent head or neck trauma (within 2 weeks)
- •Current use of blood thinning (anticoagulant), low dose aspirin, or steroid drug
研究组 & 干预措施
Arm 1
Experimental
干预措施: Acetylsalicylic acid (Aspirin, BAY1019036) (Drug)
Arm 2
Active Comparator
干预措施: Acetaminophen (Drug)
Arm 3
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)
时间窗: Up to 2 hours post-dose
次要结局
- Time to first intake of rescue medication(Up to 2 hours)
- Time to first perceptible relief(Up to 2 hours post-dose)
- Time to first perceptible relief confirmed(Up to 2 hours post-dose)
- Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)(At baseline, 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication)
- Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)(Up to 2 hours)
- Summed time weighted total pain relief scores over first hour (TOTPAR0-1)(Up to 1 hour)
- Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)(Up to 2 hours)
- Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)(At 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication)
- Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)(Up to 1 hour)
- Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)(Up to 2 hours)
- Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)(Up to 1 hour)
- Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent(At 2 hours post-dose or immediately before the first intake of rescue medication, whichever is earlier)
- Cumulative proportion of subjects taking rescue medication by time point(Up to 2 hours)
- Safety variable will be summarized using descriptive statistic based on adverse events collection(Up to 5 days post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common ColdPharyngitisTonsillitisCommon ColdNCT01465009Bayer508
已完成
3 期
Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back PainLow Back PainNCT01028079Bayer338
已完成
3 期
Acetylsalicylic Acid Combined With Pseudoephedrine in Common ColdCommon ColdNCT00963443Bayer833
已完成
1 期
Safety, Efficacy and Pharmacokinetics of ALD403MigraineNCT01772524Alder Biopharmaceuticals, Inc.163
终止
早期 1 期
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosisClinical High Risk for PsychosisNCT02047539Yale University1